about-us-img
China International Medical Tourism Co., Ltd.

An institution that provides global customers with advanced medical technology services and solutions for medical fee payment

  • The company cooperates with hospitals in China, Japan, the United States, and other regions to assist patients with international travel and receiving medical services quipped with advanced technology.
  • As a global medical platform, the company integratesglobal oncologist and new drugs and technologies, helping thousands of patientswith tumors in China, the United States, and Japan to receive new drugs andtechnologies consultation and treatment every year, and also assists numerousinternational patients to go to China for anticancer therapies such as CAR-T,TILs, and cancer vaccines.

An antitumor assistant for patients with tumors

A medical platform for oncologist

A close partner of innovative antitumor drug manufacturers

Continue to fight cancers hand in hand with global patients, and conquer cancer as early as possible!

Jointly Creating an Integrated CAR-T Treatment Service Platform for International Patients

Providing Global Patients with High-quality CAR-T Treatment Experiences and Hopes for Cure

about-us-icon
Fucaso® (Equecabtagene Autoleucel Injection)

-- The World's First Approved Fully Human CAR-T Therapy

Breakthrough fully human CAR structure
  • Full epitope of light and heavy chains binds tightly to BCMA
  • Fast dissociation, low exhaustion
  • Low immunogenicity
Durable persistence
  • Median duration of persistence time 419 days
  • 12-month sustained MRD negativity rate 81.7%
  • 12-month PFS rate 85.5%
Strong efficacy
  • ORR 98.9%
  • ≥CR rate 82.4%
  • MRD negativity rate 97.8%
Returning to life upon single-dose treatment
Excellent safety
  • No ≥ Grade 3 ICANS
  • Incidence of ≥ Grade 3
  • No movement/cognitive disorder observed No Parkinson's disease found